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A B S T R A C T
Purpose
The clinical consequences of PMS2 germline mutations are poorly understood compared with
other Lynch-associated mismatch repair gene (MMR) mutations. The aim of this European cohort
study was to define the cancer risk faced by PMS2 mutation carriers.
Methods
Data were collected from 98 PMS2 families ascertained from family cancer clinics that included a
total of 2,548 family members and 377 proven mutation carriers. To adjust for potential
ascertainment bias, a modified segregation analysis model was used to calculate colorectal cancer
(CRC) and endometrial cancer (EC) risks. Standardized incidence ratios (SIRs) were calculated to
estimate risks for other Lynch syndrome–associated cancers.
Results
The cumulative risk (CR) of CRC for male mutation carriers by age 70 years was 19%. The CR
among female carriers was 11% for CRC and 12% for EC. The mean age of CRC development
was 52 years, and there was a significant difference in mean age of CRC between the probands
(mean, 47 years; range, 26 to 68 years) and other family members with a PMS2 mutation (mean,
58 years; range, 31 to 86 years; P  .001). Significant SIRs were observed for cancers of the small
bowel, ovaries, breast, and renal pelvis.
Conclusion
CRC and EC risks were found to be markedly lower than those previously reported for the other
MMR. However, these risks embody the isolated risk of carrying a PMS2 mutation, and it should
be noted that we observed a substantial variation in cancer phenotype within and between
families, suggesting the influence of genetic modifiers and lifestyle factors on cancer risks.
J Clin Oncol 33:319-325. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Lynch syndrome (LS) is the most common heritable
colorectal carcinoma (CRC) syndrome and is respon-
sible for 2% to 4% of all CRC cases in the Western
world.1 The underlying cause of LS is a pathogenic
heterozygous germline mutation in MLH1, MSH2,
MSH6, PMS2, or EPCAM. Previous clinical stud-
ies focused primarily on patients with heterozy-
gous mutations in the MLH1, MSH2, and MSH6
genes1-5 and reported high risks for the devel-
opment of colorectal, endometrial, and other
cancers including ovarian, small bowel, pancre-
atic, gastric, urothelial, breast, and possibly
prostate carcinomas.
Although PMS2 involvement in LS was de-
scribed around the same time as that for MSH2 and
MLH16, technical difficulties in analyzing the PMS2
gene as a result of a large number of pseudogenes has
possibly led to underreporting of PMS2 mutations
in patients with LS. Several strategies to overcome
this problem, such as the design of long-range am-
plicons7,8 and RNA analysis,9 have led to improve-
ments in PMS2 mutation detection. As a result of the
relatively recent development of improved PMS2
mutation diagnostic procedures, clinical reports
concerning heterozygous PMS2 mutation carriers
published thus far include quite small cohorts.10-12
These studies reported a lower PMS2 mutation
penetrance for CRC and endometrial cancer (EC)
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compared with MLH1 and MSH2 mutation carriers and similar or
even lower risks as compared with MSH6 mutation carriers.1,5,13 Fur-
thermore, parents and other family members of biallelic PMS2 muta-
tion carriers rarely develop CRC or other LS-related cancers,14
indicating a reduced penetrance for cancer in these heterozygous
family members. One theory regarding the lower penetrance of PMS2
mutations is that MLH1/MLH3 and/or MLH1/PMS1 heterodimers
partially compensate for the loss of MLH1/PMS2, although it is worth
noting that this mechanism has not yet been confirmed by functional
studies.15
Establishing an accurate cancer risk for mutations in cancer
susceptibility genes such as PMS2 is difficult because families are
likely to be ascertained based on the severity of their phenotype and
outcomes are thus variable depending on family selection and
methods of data analysis (eg, correction for ascertainment bias). In
this study, using a modified segregation analysis, we aimed to
achieve a reliable estimate of the cancer risk for heterozygous PMS2
germline mutation carriers by including confirmed carriers to-
gether with nontested family members.
METHODS
Data Collection
All probands (index patients) included in the study were referred to a
cancer family clinic because of an LS-associated cancer or because of a sus-
pected family history. They all had a confirmed pathogenic germline mutation
in the PMS2 gene. Available pedigree and patient-specific data were collected
from 2009 until 2012, in collaboration with the clinical genetic departments of
university hospitals in the Netherlands, Norway, Germany, Sweden, Den-
mark, and Spain and the Leiden-based Netherlands Foundation for the Detec-
tion of Hereditary Tumors (Appendix Table A1, online only). The majority of
patients were of white northern European origin.
Mutation screening of the probands was performed between 2007 and
2012. PMS2 mutation analysis was initiated in most patients based on histo-
logic investigations of the tumor suggestive for a PMS2 germline defect and/or
on a family’s compliance with the Bethesda criteria.16 In addition, eight fami-
lies were recognized via a proband with biallelic PMS2 mutations. Patients
with biallelic PMS2 mutations have a distinct phenotype, with a typical spec-
trum of tumors at a young age, so they were excluded from the cancer risk
analysis (Data Supplement).17-19
Informed consent was obtained according to protocols approved by
local ethical review boards (Leiden University Medical Center Ethics Review
Board, No. P01.019). Clinical and pathologic data confirming the diagnosis,
where available, were obtained from patient records.
Mutation Analysis of PMS2
Mutation detection analysis of the PMS2 gene was performed in
multiple laboratories using a variety of methods all aimed at avoiding
interference by pseudogenes. These methods included exon-by-exon DNA
sequencing of exons 1 to 11 and simultaneous reverse transcriptase poly-
merase chain reaction (RNA analysis) of the whole coding region of PMS2
and/or long-range DNA amplicons that avoid pseudogene amplifica-
tion.7,8 Multiplex ligation-dependent probe amplification was used to
detect large genomic deletions and duplications. PMS2 mutations were
classified as deleterious based on introduction of a premature stop codon,
either directly as a result of a nonsense mutation or as a result of a
frameshift mutation, or when a deleterious splice site mutation was iden-
tified. Missense mutations were classified as deleterious based on previous
studies.9,20 Mutations are provided in the Data Supplement.
Statistical Analysis
Cancer risk analysis was based on full pedigree information. A previously
described protocol was used for the imputation of unknown dates of birth and
death from the known dates of their family members. Unknown age at cancer
diagnosis was, if possible, imputed from the cohort-, period-, and sex-specific
mean age at cancer diagnosis in the general population.21 Family members
were considered to be at risk from birth until the first occurrence of any of the
following events: first CRC diagnosis (n  208); EC diagnosis (n  39); other
cancer diagnosis (n  218); death; last contact of a family member with the
study center or last DNA test of a family member; and 70th birthday. CRC and
EC risks were estimated using modified segregation analysis implemented in
the pedigree analysis software MENDEL (University of California, Los Ange-
les, Los Angeles, CA), as previously described.12,22 Restricting the analysis to
confirmed carriers would bias the results because affected family members and
those with a strong family history of cancer might be more inclined to pursue
mutation testing and deceased individuals would be excluded. The MENDEL
program weighs the likelihood contributions of untested individuals accord-
ing to their probability of being a carrier, which was estimated from their
cancer history, age, and position in the pedigree. In the analysis, the penetrance
function was modeled in terms of the incidence rates in carriers and noncar-
riers. The incidence rates were assumed to follow a Cox proportional hazards
model in which the noncarriers were assumed to conform to population
incidence rates. These population rates were calculated using combined calen-
dar and age-specific incidences from the Netherlands and age-specific rates for
the other European countries. All country-specific incidence rates contributed
to the mean according to their weight in the total number of families. The
relative risk represents the incidence rate in mutation carriers compared with
the population incidence rates at age t. A single autosomal dominant model
and a mutation frequency of 0.001 for PMS2 were used. The incidences for
each disease at age (t) were assumed to follow a Cox model: (t)  0(t)
exp[G(t)], where 0(t) is the age-specific disease incidence rate and exp[G(t)]
is the age-specific hazard ratio (HR) or the relative risk in carriers compared
with noncarriers.
To estimate the risk of other LS-associated cancers, we calculated the
standardized incidence ratio (SIR) in a separate analysis as the ratio of
observed cancers in the cohort to the expected cancers derived from the
age-, sex-, calendar period–, and site-specific Dutch cancer population
incidence rates. We restricted the cohort analysis to known Dutch muta-
tion carriers who were alive and free of cancer in 1960 or born after 1960
(n  276). Two-sided statistical significance levels for the SIRs were esti-
mated, and 95% CIs were calculated under Poisson distribution of the
observed frequencies. Comparative analyses of mean age of cancer devel-
opment were performed via an independent samples t test in IBM SPSS
Statistics 20 (SPSS, Chicago, IL).
RESULTS
Our cohort included 98 separate families with 377 proven mutation
carriers, of whom 11 were biallelic carriers and 366 were heterozygous
carriers. Cohort characteristics are listed in Table 1.
CRC and EC
The cumulative CRC risk (Table 2; Fig 1) calculated using
MENDEL was 18.75% (95% CI, 5.60% to 30.06%) for males at age 70
years, with an HR of 6.92 (95% CI, 2.46 to 19.42). The CRC risk at age
70 years for female carriers was 10.56% (95% CI, 2.42% to 18.01%),
with an HR of 4.71 (95% CI, 1.51 to 14.72), whereas the cumulative
risk at age 70 years for EC (Table 2; Fig 2) was 11.78% (95% CI, 2.61%
to 20.09%), with an HR of 8.74 (95% CI, 2.14 to 35.7). The mean age
of first CRC development for all patients with a heterozygous PMS2
mutation was 52 years (range, 26 to 86 years; Table 3). Notably, the age
distribution for CRC differed markedly between probands and CRC-
affected family members (Appendix Figs A1 and A2, online only); the
mean ages of CRC diagnosis in these groups were 47 years (range, 26 to
68 years) and 58 years (range, 31 to 86 years), respectively. There was
ten Broeke et al
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no significant difference in mean age of CRC development between
male and female carriers (51 v 52 years, respectively; P  .83). The
mean age at diagnosis of EC was 55 years (range, 35 to 81 years), with
no significant difference between probands and affected family mem-
bers (P  .76, Table 3). For both CRC and EC, the mean age at
diagnosis of carriers of a pathogenic PMS2 mutation was higher when
compared with carriers of a MLH1 or MSH2 mutation, but when
compared with MSH6, the mean age at diagnosis of CRC was lower
and the mean age at diagnosis of EC was similar in our cohort (Ap-
pendix Table A2, online only).
Other LS-Associated Cancers
Risks for cancers other than CRC or EC among PMS2 mutation
carriers are listed in Table 4. Significant SIRs were identified for can-
cers of the small bowel (SIR, 118.9; 95% CI, 38.6 to 277.4), ovaries
(SIR, 12.0; 95% CI, 3.3 to 30.7), breast (SIR, 3.8; 95% CI, 1.9 to 6.8),
and renal pelvis (SIR, 50.5; 95% CI, 6.1 to 182.4).
DISCUSSION
In an effort to achieve a comprehensive understanding of the cancer
risks faced by PMS2 mutation carriers, we collected and analyzed a
Table 1. Cohort Description of the 98 Families
Characteristic
No. of Family Members
Total Male Female
Total 2,548 1,284 1,262
Mutation carriers 377 172 205
Homozygotes 11 5 6
Non–mutation carriers 237 108 129
CRC 208 118 90
EC 39 — 39
Other cancer 218 108 110
Lip 1 1 0
Hypopharynx 1 1 0
Lymphoma of pharynx 1 1 0
Esophagus 5 3 2
Stomach 16 8 8
Small intestine, including duodenum 8 5 3
Liver and extrahepatic bile ducts 3 1 2
Pancreas 4 1 3
Other and ill-defined sites within the digestive
organs and peritoneum 1 0 1
Nasal cavities, middle ear, and accessory
sinuses 1 1 0
Trachea, bronchus, and lung 29 27 2
Bone and articular cartilage 1 0 1
Connective and other soft tissue 1 0 1
Malignant melanoma of the skin 6 3 3
Skin 10 8 2
Female breast 44 — 44
Kaposi’s sarcoma 1 0 1
Cervix uteri 7 — 7
Ovary and other uterine adnexa 10 — 10
Other and unspecified female genital organs 1 — 1
Prostate 18 18 —
Testis 3 3 —
Bladder 5 5 0
Kidney and other and unspecified urinary
organs 8 4 4
Brain 5 3 2
Thyroid gland 4 3 1
Secondary and unspecified malignant
neoplasm of lymph nodes 1 1 0
Secondary malignant neoplasm of respiratory
and digestive systems 7 1 6
Other malignant neoplasms of lymphoid and
histiocytic tissue 3 0 3
Multiple myeloma and immunoproliferative
neoplasms 1 1 0
Leukemia of unspecified cell type 8 6 2
Unknown origin 4 3 1
NOTE. Number of cancers excludes the cancers of the biallelic muta-
tion carriers.
Abbreviations: CRC, colorectal carcinoma; EC, endometrial carcinoma.
Sex was unknown for two individuals.
Table 2. Age-Specific HRs and Cumulative Cancer Risks for CRC and EC in
PMS2 Mutation Carriers
Cancer and
Age HR 95% CI CR (%) 95% CI (%)
CRC male
 40 years 20.59 3.27 to 129.60 1.27 0.00 to 3.51
40-49 years 17.06 5.15 to 56.50 4.63 0.01 to 9.04
50-59 years 3.66 1.29 to 10.38 7.11 1.76 to 12.17
60-69 years 6.92 2.46 to 19.42 18.75 5.60 to 30.06
CRC female
 40 years 8.82 0.72 to 107.55 0.46 0.00 to 1.52
40-49 years 2.63 0.27 to 25.68 0.92 0.00 to 2.42
50-59 years 5.99 1.99 to 18.00 4.74 0.22 to 9.05
60-69 years 4.71 1.51 to 14.72 10.56 2.42 to 18.01
EC
 40 years 20.03 0.58 to 688.70 0.19 0.00 to 0.84
40-49 years 7.81 0.81 to 74.80 0.69 0.00 to 2.79
50-59 years 16.18 5.81 to 45.06 7.11 0.52 to 13.26
60-69 years 8.74 2.14 to 35.70 11.78 2.61 to 20.09
Abbreviations: CR, cumulative risk; CRC, colorectal carcinoma; EC, endome-























Male PMS2 mutation carriers
95% CI lower boundary male
95% CI upper boundary male
Female PMS2 mutation carriers
95% CI lower boundary female
95% CI upper boundary female
40 50 60 70 80
Fig 1. Graphic presentation of cumulative colorectal cancer (CRC) risk with
95% CIs.
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cohort of 98 PMS2 mutation–positive families including more than
2,500 family members. Analysis of this large cohort revealed that
cumulative CRC risk at age 70 years is almost 19% for males and 11%
for females, whereas risk for EC is approximately 12%. Furthermore,
we found significant SIRs for cancers of the small bowel, breast, ova-
ries, and renal pelvis. As reported previously for other mismatch repair
genes (MMR), females appear to have a markedly lower CRC risk
compared with males, although this observation was not statistically
significant in our study. The calculated CRC and EC risks in our study
agree with those reported by Senter et al12 who used the same statistical
methodology to calculate cancer risks in a cohort of 55 PMS2
mutation–positive families. Incontrast,cumulativecancerrisksatage70
yearsreportedforMLH1andMSH2rangefrom52%to97%forCRCand
21% to 54% for EC.1 Far closer to the risks found in our study are the
reported risks for carriers of MSH6 mutations that ranged from 22% to
69% for CRC to 16% to 71% for EC1; thus, MSH6 and PMS2 mutations
seem to represent significantly lower risks to these carriers.
A striking finding in this study is that cancer risk seems to vary
widely between members of the same family and does not seem to be
solely dependent on an individual’s PMS2 mutation status. This is
illustrated by the wide age range at initial CRC diagnosis (26 to 86 years
old) and the large difference in mean age (10 years) between probands
and mutation-positive family members. The observed heterogeneity
of risk between mutation carriers agrees with the findings of Dowty et
al,4 who also described this phenomenon for MLH1 and MSH2 mu-
tation carriers. These authors proposed that lifetime CRC risk for both
male and female mutation carriers (from birth to age 70 years) follows
a U-shaped distribution rather than a normal distribution. This means
that most MMR carriers have either a high risk or a low risk of
developing CRC, with a relatively low proportion of carriers at mod-
erate risk.4
One explanation of this high variance may be the presence of
internal (eg, genetic) or external (eg, lifestyle) modifiers. Indeed, cer-
tain single nucleotide polymorphisms associated with a slight increase
in CRC risk in the general population, as found by genome-wide
association studies, are known to significantly influence CRC risk in
patients with LS with MLH1 and MSH2 mutations.23,24 Lifestyle fac-
tors, such as body mass index and smoking, have also been reported to
modify CRC risk and adenoma development in patients with LS.25,26
This is possibly explained by a difference in the molecular mechanism
underlying carcinogenesis in patients with LS that might then result in
lifestyle factors having a different effect in these patients compared
with patients with sporadic CRC. However, because previous associ-
ation studies only include limited numbers of PMS2 mutation carri-
ers, further research on this subject is needed.
Because of the increased identification of PMS2 mutation carri-
ers (and patients with LS in general) expected to result from the
implementation of next-generation sequencing and universal screen-
ing programs for patients with CRC and EC, there is now a pressing
need to establish PMS2-specific risk estimates. This increased detec-
tion is illustrated by studies using immunohistochemistry analysis in
CRCs from population-based cohorts that showed that isolated PMS2
protein loss in the tumor, which is indicative of a germline PMS2
mutation, occurs in 0.5% to 1.5% of unselected patients with
CRC.12,15,27 Previously, identification of patients with LS was based on
strict Amsterdam and/or Bethesda selection criteria, but recent
population-based CRC and EC studies have shown that more than
half of patients identified with an LS-like profile do not comply with
these criteria and probably would have been missed in the past.27,28
This problem is even more relevant to PMS2 families because it is
likely that they do not comply with strict selection criteria as a result of
low cancer penetrance and a higher mean age at cancer development
( 50 years).12 Even in our selected cohort, only 19% of the families
complied with the Amsterdam II criteria and 78% with the revised
Bethesda criteria.16,29 Almost 22% of the families in our cohort failed
to comply with any of the previously mentioned criteria and would
have been overlooked based on these criteria alone. The possible
current underestimation of PMS2 mutation–positive families is fur-
ther suggested and illustrated by next-generation sequencing studies
in which PMS2 mutations were reported as incidental findings in
0.03% to 0.4% of individuals not selected based on CRC.30-32
Identifying MMR mutation carriers is important because these
individuals should be enrolled in surveillance programs. Currently, LS
family members are advised to participate in colonic surveillance at 1-
to 2-year intervals beginning at approximately 20 to 25 years of
age.33,34 We now suggest that surveillance in PMS2 mutation carriers
could start at a slightly higher age (eg, 30 years, similar to the previ-























Female PMS2 mutation carriers
95% CI lower boundary
95% CI upper boundary
40 50 60 70 80
Fig 2. Graphic presentation of cumulative endometrial cancer (EC) risk with
95% CIs.





Age at Diagnosis (years)
PMedian Mean Range
CRC
Total group 106 51 52 26-86 .83
Male 65 52 51 26-86
Female 41 51 52 27-78
Probands 62 48 47 26-68  .001
Family members 44 57 58 31-86
EC
Total group 25 54 55 35-81
Probands 15 52 56 42-81 .76
Family members 10 58 54 35-68
Abbreviations: CRC, colorectal carcinoma; EC, endometrial carcinoma.
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of onset and lower cancer risk than that reported for MLH1 and
MSH2.35 It should be noted, however, that six heterozygous probands
(six [1.6%] of 366 mutation carriers) developed CRC at age 30 years or
younger. Interestingly, their mutation-positive family members with
CRC had a significantly later age of onset (56 years as opposed to 28
years). Moreover, none of the heterozygous family members in our
cohort developed CRC before the age of 30 years (Appendix Figures
A1 and A2, online only).
The efficacy of surveillance for EC is less well established. How-
ever, surveillance is currently still advised and consists of gynecologic
examination with transvaginal ultrasound and/or hysteroscopy with
aspiration biopsy, starting at the age of 30 to 35, which may lead to the
detection of premalignant disease.33,34,36 Prophylactic surgery (ie,
risk-reducing salpingo-oophorectomy) does not seem to be appropri-
ate for female PMS2 mutation carriers because mortality from EC is
relatively low.37 Indeed, in our cohort, only one of 25 proven PMS2
mutation carriers with EC died of EC, at age 65. Furthermore, ovarian
cancer in patients with LS predominantly presents in early stages of
carcinogenesis, and there is evidence that surveillance (transvaginal
ultrasound and CA-125) might have a greater efficacy in these patients
than in patients with non–LS-related ovarian cancer.38 Therefore, we
only advise use of the surveillance protocol described earlier and not
prophylactic surgery.
Additional screening for other LS-associated cancers is currently
not advised for patients with LS, except in the case of familial clustering
of gastric or urinary tract cancer.33,39 Our cohort of PMS2 mutation
carriers showed significant SIRs for cancers of the small bowel, ovaries,
renal pelvis, and breasts (Table 4). The first three cancers are accepted
as part of the LS tumor spectrum, but the association of breast
cancer with germline MMR mutations is currently still a subject of
debate.1 Because of a relatively low incidence and, in general, a high
mean age at diagnosis in our cohort (Table 4), additional surveil-
lance other than for CRC and EC does not seem to be indicated.
However, in light of an SIR of 3.8 for breast carcinomas, mammog-
raphy from age 40 years may be considered, especially in PMS2
families that show clustering of breast cancer. The relatively small
number of patients in the current study and the low frequency of
some LS-associated cancers mean that a larger cohort will be re-
quired to formulate definitive conclusions and advice.
Besides the implications for surveillance, the risks reported
here also have implications for counseling of PMS2 mutation car-
riers. Although it is our opinion that gene-specific counseling is
justified, it should be clearly explained to patients that these risk
estimates were corrected for ascertainment and embody the risk of
the PMS2 mutation itself. These unbiased risks are probably most
applicable for patients with a PMS2 mutation identified via
population-based screening programs (and not selected based on
their family history of cancer) or as an incidental finding of next-
generation sequencing diagnostics now being introduced in many
laboratories. However, given that in daily clinical practice, most
PMS2 mutation carriers will still be identified as members of a
family severely affected with cancer, it is probable that other ge-
netic or environmental risk factors that contribute to a higher
cancer risk are present in these families.
In conclusion, the cumulative CRC and EC risks for PMS2
mutation carriers are markedly lower than the current risk esti-
mates for LS familiar to clinicians, and a significant proportion of
these families are probably missed because of strict selection crite-
ria. In addition, the wide within-family variance suggests that other
risk factors are present in most families. While awaiting the advent
of personalized risk stratification, we suggest a limited modifica-
tion of surveillance guidelines for PMS2 mutation carriers similar
to that for MSH6, which is to begin colorectal surveillance at age 30
years instead of the current 25 years of age. Furthermore, prophy-
lactic removal of the uterus and ovaries of female PMS2 mutation
carriers does not seem advisable at the present time.
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Overall cancer 35 16.9 2.1 1.4 to 2.9  .001 57 18-80
Small bowel 5 0.042 118.9 38.6 to 277.4  .001 60 48-79
Breast 11 2.9 3.8 1.9 to 6.8  .001 55 36-80
Ovary 4 0.33 12.0 3.3 to 30.7  .001 55 51-59
Prostate 2 1.17 1.7 0.21 to 6.2 .66 56 42-70
Renal pelvis 2 0.040 50.5 6.1 to 182.4 .0015 78 77-79
Brain 1 0.37 2.7 0.069 to 15.2 .62 55
Leukemia† 1 0.47 2.1 0.054 to 11.9 .75 45
Stomach 0 0.57 0 0 to 6.5 NA
Pancreas 0 0.31 0 0 to 12 NA
Bladder 1 0.50 2.0 0.051 to 11.2 .79 49
NOTE. The standardized incidence ratio is the observed number of cancers divided by the number of expected cancers in the general population.
Abbreviations: CRC, colorectal carcinoma; EC, endometrial carcinoma; NA, not applicable.
Excluding CRC and EC.
†Non-Hodgkin lymphoma.
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GLOSSARY TERMS
cumulative risk: a measure of risk of an event (usually dis-
ease occurrence) during a specified time period.
germline mutation: an inherited variation in the lineage of
germ cells. Germline mutations can be passed on to offspring.
immunohistochemistry: the application of antigen-
antibody interactions to histochemical techniques. Typically, a
tissue section is mounted on a slide and incubated with anti-
bodies (polyclonal or monoclonal) specific to the antigen (pri-
mary reaction). The antigen-antibody signal is then amplified
using a second antibody conjugated to a complex of
peroxidase-antiperoxidase, avidin-biotin-peroxidase, or
avidin-biotin alkaline phosphatase. In the presence of sub-
strate and chromogen, the enzyme forms a colored deposit at
the sites of antibody-antigen binding. Immunofluorescence is
an alternate approach to visualize antigens. In this technique,
the primary antigen-antibody signal is amplified using a sec-
ond antibody conjugated to a fluorochrome. On ultraviolet
light absorption, the fluorochrome emits its own light at a longer
wavelength (fluorescence), thus allowing localization of antibody-
antigen complexes.
Lynch syndrome: hereditary nonpolyposis colorectal cancer
(HNPCC). A cancer syndrome characterized by Henry T. Lynch in 1966,
this genetic condition has a high risk of colon cancer as well as other cancers
including endometrial, ovary, stomach, small intestine, hepatobiliary tract,
upper urinary tract, brain, and skin.
mismatch repair genes (MMR): genes that recognize and cor-
rect errors in DNA replication leading to single base-pair mismatches or
insertions/deletions in small repetitive tracts of DNA known as micro-
satellites.
phenotype: the overall appearance of an organism, or the observable
expression of a specific trait, determined by its genotype and environ-
mental factors.
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Appendix
Table A1. Family Country of Origin







Table A2. Mean Age at Cancer Diagnosis of Mismatch Repair Gene Mutation Carriers
Cancer
PMS2 MLH1/MSH24 MSH65
Mean Age (years) Range (years) Mean Age (years) Range (years) Mean Age (years) Range (years)
CRC
Including probands 52 26-86 59 30-90
Excluding probands 58 31-86 47 15-95
EC
Including probands 55 35-81 54 32-82
Excluding probands 54 35-68 47 26-75
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Fig A1. Histogram of mean age of colorectal cancer (CRC) development in probands with a heterozygous PMS2 mutation. The gray line indicates age 30 years, which
is the suggested start of colorectal surveillance.
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Fig A2. Histogram of mean age of colorectal cancer (CRC) development in family members with a heterozygous PMS2 mutation. The gray line indicates age 30 years,
which is the suggested start of colorectal surveillance.
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